Author

L. Russell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1 Zoology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:E. coli· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:non-human primate· 1

Frequent Co-Authors

A. Baum· 1 shared A. Filby· 1 shared A. Fuller· 1 shared A. Isa· 1 shared A. Moorman· 1 shared A. Rusnak· 1 shared A. S. Putnam· 1 shared A. Wilson· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Baum

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Endangered Przewalski's horse, Equus przewalskii, cloned from historically cryopreserved cells

B. J. Novak, O. A. Ryder, M. L. Houck, A. S. Putnam, K. Walker, L. Russell, B. Russell, S. Walker, S. S. Arenivas, L. Aston, G. Veneklasen, J. A. Ivy, K.-P. Koepfli, A. Rusnak, J. Simek, , R. Phelan

The paper reports the cloning of two endangered Przewalski's horse stallions from cryopreserved fibroblast cells, marking the first successful production of multiple healthy clones for an endangered species.

bioRxiv · Dec 20, 2023Zoology

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine

K. W. Peng, T. Carey, P. Lech, R. Vandergaast, M. A. Munoz-Alia, N. Packiriswamy, C. Gnanadurai, K. Krotova, M. Tesfay, C. Ziegler, M. Haselton, K. Sevola, C. Lathrum, S. Reiter, R. Narjari, , S. J. Russell

This study develops an oral rhabdoviral vaccine that boosts SARS-CoV-2 immunity in nonhuman primates by enhancing viral tropism through G protein trans-complementation.

bioRxiv · Oct 16, 2021Immunology

An ex vivo human bone marrow milieu identifies CDH2 as a driver of niche-mediated treatment resistance in leukaemia

D. Pal, H. Blair, S. Boyd, S. Angel, S. Nizami, A. Isa, M. Beckett, R. Nelson, A. Wilson, M. Singh, S. Sankar, R. Tirtakusuma, S. Nakjang, C. Knill, A. Fuller, , J. Vormoor

This study identifies CDH2 as a driver of niche-mediated treatment resistance in leukemia and shows that ADH-1 can effectively target this resistance in preclinical models.

bioRxiv · Jun 18, 2021Cancer Biology